[1]
Bianchera, A.; Alomari, E.; Bruno, S. Augmentation therapy with alpha 1-antitrypsin: present and future of production, formulation and delivery. Curr. Med. Chem., 2022, 29(3), 385-410.
[2]
Cioni, P.; Gabellieri, E.; Campanini, B.; Bettati, S.; Raboni, S. Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications. Curr. Med. Chem., 2022, 29(3), 411-452.
[3]
Garg, H.; Tatiossian, K.; Peppel, K.; Kato, G.J.; Herzog, E. Gene therapy as the new frontier for Sickle Cell Disease. Curr. Med. Chem., 2022, 29(3), 453-466.
[4]
Karnaukhova, E. C1-Inhibitor: Structure, Functional Diversity and Therapeutic Development. Curr. Med. Chem., 2022, 29(3), 467-488.
[5]
Marchetti, M.; Faggiano, S.; Mozzarelli, A. Enzyme Replacement Therapy for Genetic Disorders Associated with Enzyme Deficiency. Curr. Med. Chem., 2022, 29(3), 489-525.
Current Medicinal Chemistry
Title:Targeted Biologics: The New Frontier for Precision Therapy
Volume: 29 Issue: 3
Author(s): Stefano Bruno, Paul W. Buehler and Andrea Mozzarelli
Affiliation:
Export Options
About this article
Cite this article as:
Bruno Stefano, Buehler Paul W. and Mozzarelli Andrea, Targeted Biologics: The New Frontier for Precision Therapy, Current Medicinal Chemistry 2022; 29 (3) . https://dx.doi.org/10.2174/092986732903220103161049
DOI https://dx.doi.org/10.2174/092986732903220103161049 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Article Metrics

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements